Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
- Model
- Manufacturer
- Manufacturer?
- Yes
Leuprolide is a GnRH agonist used in prostate cancer and endometriosis (Lupron).
12 listed companies hold an active US Type II Drug Master File for Leuprolide API, based in India (5), Switzerland (2), China (2), Spain (1), Taiwan (1), Italy (1). 9 have a regulator record of GMP manufacturing, and 1 carries an open FDA warning letter.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Source: FDA Drug Master File list. Holding a DMF is a regulatory filing, not an FDA approval.
Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
Privately owned Barcelona peptide CDMO founded in 1989, making GMP generic peptide APIs and custom NCE peptides. Holds US DMFs for 10 peptide APIs.
Indian CDMO whose Turbhe, Navi Mumbai site develops and makes peptide APIs by solid- and solution-phase synthesis. Holds US DMFs for 9 peptide APIs.
Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.
Peptide-focused CDMO running GMP manufacturing sites on three continents.
API manufacturer and CDMO focused on complex generics, including peptides.
Beijing API company, founded 2006, that holds DMFs and has its APIs made in partner facilities under its own quality control. Holds US DMFs for 13 peptide APIs.
Italian API maker in the Italfarmaco Group, founded 1973, producing peptides since 1996; US DMFs for leuprolide and octreotide.
Mumbai peptide API maker acquired by Piramal Pharma in 2021; its oxytocin API is WHO-prequalified; US DMF for oxytocin.
Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.
Mumbai-based generics group that makes APIs and finished medicines. Holds US Type II DMFs for 15 peptide APIs, including GLP-1s and GnRH analogues.
Companies holding active US DMFs for Leuprolide include Alembic Pharmaceuticals Ltd, Auro Peptides Ltd, BCN Peptides SA, Piramal Pharma Ltd (Piramal Pharma Solutions), Bachem Holding AG, PolyPeptide Group, ScinoPharm Taiwan, ALP Pharm Beijing Co., Ltd., Chemi S.p.A., Hemmo Pharmaceuticals Pvt Ltd (Piramal Pharma Solutions) and 2 more. Other manufacturers may supply it without a US DMF.
Among listed DMF holders: India (5), Switzerland (2), China (2), Spain (1), Taiwan (1), Italy (1).
Sun Pharmaceutical Industries Ltd has an open FDA warning letter, shown on the listing and in the FDA enforcement tracker.
No. FDA reviews a DMF when a drug application references it and does not approve DMFs on their own.